Serena De Matteis
Overview
Explore the profile of Serena De Matteis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
518
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
De Matteis S, Del Coco L, Castro F, Giudetti A, Casadei B, Iannotta F, et al.
Haematologica
. 2024 Dec;
PMID: 39704157
Plasma metabolomics analysis was performed on 44 patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r/B-NHL) infused with approved CD19.CAR-T cell products at the time of pre-lymphodepletion (PLD) and at day +1,...
2.
Ursi M, Kwiatkowska K, Pirazzini C, Storci G, Messelodi D, Bertuccio S, et al.
Haematologica
. 2024 Oct;
110(2):481-484.
PMID: 39363850
No abstract available.
3.
Storci G, De Felice F, Ricci F, Santi S, Messelodi D, Bertuccio S, et al.
J Clin Invest
. 2024 Jun;
134(14).
PMID: 38833312
BACKGROUNDPredicting immune effector cell-associated neurotoxicity syndrome (ICANS) in patients infused with CAR T cells is still a conundrum. This complication, thought to be consequent to CAR T cell activation, arises...
4.
Del Duca F, Napoletano G, Volonnino G, Maiese A, La Russa R, DI Paolo M, et al.
Front Med (Lausanne)
. 2024 Jan;
10:1272291.
PMID: 38259840
Background: CAR-T-related deaths observed worldwide are rare. The underlying pathogenetic mechanisms are the subject of study, as are the findings that enable diagnosis. A systematic literature search of the PubMed...
5.
Tumedei M, Piccinini F, Azzali I, Pirini F, Bravaccini S, De Matteis S, et al.
Int J Mol Sci
. 2023 Jun;
24(12).
PMID: 37373066
The majority of patients with Follicular Lymphoma (FL) experience subsequent phases of remission and relapse, making the disease "virtually" incurable. To predict the outcome of FL patients at diagnosis, various...
6.
Chirumbolo G, Dicataldo M, Barone M, Storci G, De Matteis S, Laprovitera N, et al.
Transplant Cell Ther
. 2023 Feb;
29(5):302.e1-302.e8.
PMID: 36796518
Chronic GVHD (cGVHD) is the major cause of long-term morbidity after allogeneic hematopoietic stem cell transplantation (HSCT). There are no biomarkers that can consistently predict its occurrence. We aimed to...
7.
De Matteis S, Dicataldo M, Casadei B, Storci G, Laprovitera N, Arpinati M, et al.
Front Immunol
. 2023 Feb;
13:1058126.
PMID: 36726971
Background: Infusion of second generation autologous CD19-targeted chimeric antigen receptor (CAR) T cells in patients with R/R relapsed/refractory B-cell lymphoma (BCL) is affected by inflammatory complications, such as Immune Effector...
8.
Storci G, Barbato F, Ricci F, Tazzari P, De Matteis S, Tomassini E, et al.
Front Immunol
. 2023 Jan;
13:1058739.
PMID: 36713433
Graft versus host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (HSCT). Rabbit anti-T lymphocyte globulin (ATLG) in addition to calcineurin inhibitors and antimetabolites is a...
9.
Maffini E, Festuccia M, Ursi M, Barbato F, Dicataldo M, Roberto M, et al.
Curr Opin Hematol
. 2022 Dec;
30(1):14-21.
PMID: 36539361
Purpose Of Review: Several studies showed that age alone should not be used as an arbitrary parameter to exclude patients from allogeneic hematopoietic cell transplantation (HCT). The accessibility to allogeneic...
10.
Maffini E, Ursi M, Barbato F, Dicataldo M, Roberto M, Campanini E, et al.
Front Oncol
. 2022 Dec;
12:1066285.
PMID: 36530990
Disease relapse represents by far the most frequent cause of hematopoietic cell transplantation (HCT) failure. Patients with acute leukemia suffering relapse after HCT have limited conventional treatment options with little...